What is Apremilast?
A PD4 (phosphodiesterase 4) inhibitor
Works intracellularly to reduce the production of pro-inflammatory mediators and increase those that are anti-inflammatory
Downregulation of pro-inflammatory cytokines:
↓ TNF-α
↓ IL-17, IL-23
↑ IL-10 (anti-inflammatory)
Dosage of apremilast
30mg BD
Rapid uptitration to reduce GI side effects, starting at 10mg a day and increased 10mg every day:
○ Day 1: 10mg mane
○ Day 2: 10mg mane + 10mg nocte
○ Day 3: 10mg mane + 20mg nocte
○ Day 4: 20mg mane + 20mg nocte
○ Day 5: 20mg mane + 30mg nocte
○ Day 6: 30mg mane + 30mg nocte
Adverse effects of Apremilast?
PBS criteria for Apremilast?
Note: effective for PsA, but not PBS listed
Contraindications for Apremilast?
Hypersensitivity
Relative:
○ Depression or suicidal ideation history, instruct patients to monitor mood
○ Pregnancy, may cause increase in pregnancy loss, but can use if risks outweigh benefits, category B3
○ Lactation: unknown if secreted in breast milk
○ Co-administration with potent CYP450 inducers (rifampicin, phenobarbital, carbamazepine, phenytoin, may diminish apremilast levels)
Pregnancy category of Apremilast?
Pregnancy, may cause increase in pregnancy loss, but can use if risks outweigh benefits, category B3
Pre Treatment Investigations for apremilast
Monitoring Ix for apremilast
Not required
T/F
- apremilast is pregnancy category C
- has a half life of 24 hours
- requires dose adjustment in hepatic failure
- requires dose adjustment in renal failure
- is not recommended in breastfeeding
F - B3
F - 6 - 9 hours
F
T - half dose (30mg OD)
T
Regarding apremilast
- is useful for PsA
- is excreted in the urine only
- is contraindicated in patients with major depression
T
F - faeces and urine
T